Precigen, Inc. · NASDAQ:PGEN
Precigen — 39th Annual J.P. Morgan Healthcare Conference (January 2021)
23 slides from Precigen's conference presentation, Jan 13, 2021
Slide 1: 39th Annual J.P. Morgan Healthcare Conference
39th Annual J.P. Morgan Healthcare Conference 13 January 2021 Helen Sabzevari, PhD President & CEO EXHIBIT 99.1
Slide 2: Forward-looking Statements
Forward-looking Statements Some of the statements made in this presentation are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon Precigen's current expectations and projecti
Slide 3: Precigen: Deploying Novel Approaches to Address Unmet Healthcare Needs
Precigen: Deploying Novel Approaches to Address Unmet Healthcare Needs L. Lactis gene removed Therapeutic gene inserted UltraCAR-T® AdenoVerse™ Immunotherapy ActoBiotics™
Slide 4: Precigen Clinical Pipeline
Precigen Clinical Pipeline PRODUCT PLATFORM INDICATION DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 PRGN-3005 UltraCAR-T Ovarian Cancer PRGN-3006 UltraCAR-T AML, MDS PRGN-2009 OTS AdenoVerse Immunotherapy HPV+ Solid Tumors PRODUCT PLATFORM INDICATION DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 AG
Slide 5: ActoBiotics Platform
ActoBiotics®Platform
Slide 6: AG019: A First-in-Class Oral Investigational Therapy in Type 1 Diabetes
Positive interim data reported from Phase 1b (monotherapy) and Phase 2a (combination) arms1: AG019 monotherapy as well as the combination of AG019 and teplizumab were well-tolerated and safe 58% (7/12) and 70% (7/10) adults showed insulin C-peptide stabilization at 6-months in monotherapy and combin
Slide 7: UltraCAR-T Platform
UltraCAR-T® Platform
Slide 8: UltraCAR-T: Overnight, Decentralized Manufacturing Process
UltraCAR-T: Overnight, Decentralized Manufacturing Process Promises a Potentially More Effective Way to Treat Patients UltraCAR-T Platform is Designed to Bring Benefits of Off-the-Shelf Allogeneic Therapy to Autologous CAR-T Treatment Non-viral multi-gene delivery Stem-like T cell memory phenotype O
Slide 9: Precigen's Potential through Differentiated Platforms: UltraCAR-T
Precigen’s Potential through Differentiated Platforms UltraCAR-T® PRGN-3005 UltraCAR-T in Ovarian Cancer Positive initial data reported from Phase 1 IP arm: PRGN-3005 treatment was safe and well-tolerated with no dose-limiting toxicities (DLTs) to date 100% manufacturing success to date Encouraging
Slide 10: UltraCAR-T Library Approach
UltraCAR-T Library Approach: Precigen’s Vision is to Transform the Personalized Cell Therapy Landscape for Cancer Patients
Slide 11: AdenoVerse Immunotherapy Platform
AdenoVerse™ Immunotherapy Platform
Slide 12: AdenoVerse: Industry-leading Adenovector Technology
AdenoVerse™: Industry-leading Adenovector Technology A Library of Adenoviral Vectors with Diverse and Unique Biological Properties is Differentiated from Competition Large genetic payload capacity Ability for repeat administration Highly productive manufacturing process Non-replicating adenoviruses
Slide 13: PRGN-2009: An Attractive Opportunity in HPV-associated Cancers
PRGN-2009: An Attractive Opportunity in HPV-associated Cancers 1Miles et al. Gynecologic Oncology Research and Practice (2017) 4:10 2 de Martel C, et al. Volume 8, ISSUE 2, e180-e190, February 01, 2020 HPV-associated Cancers: Market Opportunity PRGN-2009 Multi-epitope Antigen Design targets HPV16/18
Slide 14: PRGN-2009: A First-in-Class Investigational Therapy for HPV-associated Cancers
PRGN-2009 A First-in-Class Investigational Therapy for HPV-associated Cancers Phase 1 portion of Phase 1/2 trial is ongoing in collaboration with NCI through a CRADA Phase 1 study is evaluating safety and response of PRGN-2009 alone and in combination with M7824 (bintrafusp alfa) in patients with HP
Slide 15: Preliminary Data Show Increase in HPV-specific T Cell Response
Preliminary Phase 1 Data Demonstrate Increase in HPV-specific T Cell Response in Patients Upon Repeated Dosing of PRGN-2009 Subject 3 Enrolled at Dose Level 1 PRGN-2009 Administration CD4+ T Cell Response CD8+ T Cell Response All patients (N=6) enrolled in Phase 1 monotherapy arm (Arm A) have receiv
Slide 16: Recurrent Respiratory Papillomatosis (RRP)
Recurrent Respiratory Papillomatosis (RRP) 1Derkay and Wiatrak 2008, National Organization for Rare Disorders 2019 2Armstrong, Derkay et al. 1999 3Hermann, Pontes et al. 2012 4Seedat 2020 5National Organization for Rare Disorders 2019 6RRP Foundation: http://www.rrpf.org/whatisRRP.html 7Rodriguez-Ga
Slide 17: PRGN-2012: AdenoVerse Immunotherapy Targeting HPV6 and HPV11 for RRP
PRGN-2012: AdenoVerse Immunotherapy Targeting HPV6 and HPV11 for Recurrent Respiratory Papillomatosis (RRP) PRGN-2012 Induces Robust HPV6 and HPV11 Specific T-cell Response in RRP Patient Samples In Vitro PRGN-2012 targets HPV6 and HPV11 Gorilla adenoviral vector, with the ability for repeat injecti
Slide 18: PRGN-2012: A First-in-Class Investigational Therapy for RRP
PRGN-2012 A First-in-Class Investigational Therapy for RRP PRGN-2012 IND application to initiate Phase 1 trial in was approved by the FDA First AdenoVerse Immunotherapy to enter clinic for infectious disease indication Phase 1 study will evaluate safety and maximum tolerated dose of PRGN-2012 Patien
Slide 19: PRGN-2013: Opportunity in Chronic Hepatitis B Virus Infection
PRGN-2013: Opportunity in Chronic Hepatitis B Virus (HBV) Infection 1Center for Disease Control: https://www.cdc.gov/hepatitis/hbv/bfaq.htm 2Xie Y., Adv Exp Med Biol 2017 3World Health Organization: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b Liver infection caused by HBV may lead t
Slide 20: Summary
Summary
Slide 21: Precigen in 2020: Achieved All Anticipated Clinical Milestones
Precigen in 2020: Achieved All Anticipated Clinical Milestones Initial data released from the intraperitoneal (IP) arm of PRGN-3005 UltraCAR-T Phase 1 trial in Ovarian Cancer Initial data released from PRGN-3006 UltraCAR-T Phase 1 trial in AML and MDS Interim data released from Phase 2 trial of AG01
Slide 22: Precigen in 2021: Multiple Upcoming Milestones
Precigen in 2021: Multiple Upcoming Milestones Complete dose escalation phase and initiate expansion phase of PRGN-3005 UltraCAR-T IP arm in Ovarian Cancer. Initiate the IV arm of PRGN-3005 Phase 1 trial. Present corresponding interim data. Present interim data from PRGN-3006 UltraCAR-T Phase 1 tria
Slide 23: PRE@IG=N
ee” PRE@IG=N
Precigen — 39th Annual J.P. Morgan Healthcare Conference (January 2021) on 6ix